Cancer cells have various ways of maintaining their fatty acid levels, including increased de novo FAB.[50] ATP citrate lyase (ACLY, EC 2.3.3.8), acetyl‐CoA carboxylase (ACC, EC 6.4.1.2), and fatty acid synthase (FASN, EC 2.3.1.85) are the key enzymes responsible for lipogenesis via FAB and are targeted by anti‐proliferative therapies.[51] FAB inhibitors like epigallocatechin gallate (EGCG) and apigenin (APIG)impede lipogenesis at the FASN stage.[52, 53] Similarly, QQrB inhibits ACLY, which produces a comparable metabolite profile to EGCG and APIG.[54]. Here, FANCB is linked to cancer.